

Carboplatin Now Available Through SICOR Agreement

Effective June 24, 2004, the following products have been added to the SICOR Agreement for OA Members:

- **Carboplatin Injection**
- **Carboplatin for Injection**
- **Liquid Fludarabine**

SICOR is the first to market Carboplatin, the generic version of Paraplatin. Carboplatin is indicated for the treatment of advanced ovarian carcinoma of epithelial origin in: a) first line therapy; b) second line therapy, after other treatments have failed. Carboplatin is also indicated in the treatment of small cell carcinoma of the lung and in squamous cell carcinoma of the head and neck.

Fludarabine Phosphate Injection is the first ready-to-use solution format and is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. Ready-to use Fludarabine is available at no additional cost when compared to lyophilized Fludarabine.

For full prescribing information on Carboplatin and Fludarabine, visit www.newsicor.com. Contact OA at **888-732-7352** for any questions regarding the agreement.

NDC #	Product Description	Strength	Size	Package
00703-3244-11	Carboplatin Injection (Liquid Presentation)	50 mg	6 mL	1
00703-3264-01	Carboplatin for Injection (Lyophilized Presentation)	50 mg	6 mL	1
00703-3246-11	Carboplatin Injection (Liquid Presentation)	150 mg	20 mL	1
00703-3266-01	Carboplatin for Injection (Lyophilized Presentation)	150 mg	20 mL	1
00703-3248-11	Carboplatin Injection (Liquid Presentation)	450 mg	50 mL	1
00703-3268-01	Carboplatin for Injection (Lyophilized Presentation)	450 mg	50 mL	1
00703-4852-11	Fludarabine Phosphate Injection	50 mg	2 mL	1